Dermisonics Inc(DMSI)
USD --+0.00%
Reward40Moderate
Risk54Moderate
📊75%Data
DMSI
+0.0 · +0.00%
USD · OTCCE
Dermisonics Inc | Healthcare
Capital Destroyer
Market Cap:1917
ℹ️
Reward Rating
40
Moderate
Bottom 10% (model universe)
75% data coverage
ℹ️
Risk Rating
54
Moderate
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on DMSI to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Dermisonics Inc?

manufactures ultrasonic transdermal drug-delivery technologies and equipment.

DMSI · Verdict

Moderate reward · elevated risk

DMSI stands out on volatility and balance sheet, but watch the cash flow signal.

Based on 88% data coverage

DMSI · Verdict

What’s working & what to watch

Strengths 2

  • Volatility75/100

    Above average

  • Balance sheet68/100

    Current ratio 0.14

Watchouts 3

  • Cash flow5/100

    Weak vs peers

  • Profitability10/100

    -392% return on equity

  • Growth41/100

    Earnings +295.0% CAGR

Model-based scoring. For information only — not financial advice.

What is Dermisonics Inc?

manufactures ultrasonic transdermal drug-delivery technologies and equipment. It primarily focuses on the development, testing, and commercialization of its active transdermal patch, called the U-Strip, that has been designed to facilitate the needle-free delivery of drugs with large molecular structures, such as Insulin into the bloodstream. The company is listed on the OTCCE in USA, operating in the Healthcare sector, with a market capitalisation of 1.92K.

Financial Highlights

Investment Breakdown

📈 Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
💰 Profitability
Thin or inconsistent margins weigh on earnings quality.
⚠️ Risk
Risk profile appears balanced versus broad market conditions.
💸 Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (40)

The scoring profile indicates limited reward potential at this time, with valuation and momentum offering the most support. Risk indicators are elevated — volatility and macro sensitivity warrant consideration.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap1.92K
P/E RatioN/A
Dividend YieldN/A
52 Week HighN/A
52 Week LowN/A
Last AnnualSeptember
IPO DateN/A
IncorporatedUSA
Shares Outstanding64M
No. of EmployeesN/A
IndustryMedical Devices
ExchangeOTCCE
Beta-152.234
CurrencyUSD
WebsiteN/A